54. Ogino S, Kuchiba A, Qian ZR, et al. Prognostic significance and
molecular associations of 18q loss of heterozygosity: a cohort study of
microsatellite stable colorectal cancers. J Clin Oncol 2009; 27:4591–8.
55. Kim ST, Lee J, Park SH, et al. The effect of DNA mismatch repair
(MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol 2010;27:1277–85.
56. Sargent DJ, Monges G, Thibodeau SN, et al. Therapy in colon cancer.
J Clin Oncol 2010;28:4664.
57. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instabil-ity status as a predictor of benefit from fluorouracil-based adjuvant
chemotherapy for colon cancer. N Engl J Med 2003;349:247–57.
58. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair,
KRAS, and BRAF mutations in predicting recurrence and benefits
from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261–
59. Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant
therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses J Clin Oncol 2011;29:3768–74.
60. Chang SC, Lin JK, Lin TC, Liang WY. Loss of heterozygosity: an independent prognostic factor of colorectal cancer. World J Gastroenterol
61. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with
irinotecan, fluorouracil, and leucovorin in stage III colon cancer:
Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27:
62. Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a
study of CALGB 9581 and 89803. J Clin Oncol 2011;29:3153–62.
63. Dalerba P, et al. CDX2 as a prognostic biomarker in stage II and stage
III colon cancer. N Engl J Med 2016;374: 211–22.
64. Clark-Langone KM, Wu JY, Sangli C, et al. Biomarker discovery
for colon cancer using a 761 gene RT-PCR assay. BMC Genomics
65. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative
multigene reverse transcriptase-polymerase chain reaction assay for
assessment of recurrence risk in patients with stage II colon cancer. J
Clin Oncol 2011;29:4611–9.
66. Niedzwiecki D, Bertagnolli MM, Warren RS, et al. Documenting the
natural history of patients with resected stage II adenocarcinoma
of the colon after random assignment to adjuvant treatment with
edrecolomab or observation: results from CALGB 9581. J Clin Oncol
67. Yothers G, O’Connell MJ, Lee M, et al. Validation of the 12-gene
colon cancer recurrence score in NSABP C-07 as a predictor of
recurrence in patients with stage II and III colon cancer treated with
fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J
Clin Oncol 2013;31:4512–9.
68. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits
and by how much? J Clin Oncol 2004;22:1797–806.
69. Gill S, Loprinzi C, Kennecke H, et al. Prognostic web-based models
for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer 2011;117:
70. Jung M, Kim GW, Jung I, et al. Application of the Western-based
adjuvant online model to Korean colon cancer patients; a single
institution experience. BMC Cancer 2012;12:471.
71. Papamichael D, Renfro LA, Matthaiou C, et al. Validity of Adjuvant!
Online in older patients with stage III colon cancer based on 2967
patients from the ACCENT database. J Geriatr Oncol 2016;7:422–9.
72. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsat-
ellite instability on the pattern of metastatic spread and prognosis in
metastatic colorectal cancer. Cancer 2011;117:4623–32.
73. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and
BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC- 3, EORTC 40993, SAKK 60-00 trial. J Clin
74. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and
BRAF mutation testing in colorectal cancer prognostication. J Natl
Cancer Inst 2013;105:1151–6.
75. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic
activation of the RAS/RAF signaling pathway impairs the response of
metastatic colorectal cancers to anti-epidermal growth factor receptor
antibody therapies. Cancer Res 2007;67:2643–8.
76. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al. The
predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review
and meta-analysis. Acta Oncol 2014;53:852–64.
77. Taieb J, Le Malicot K, Shi Q, et al. Prognostic value of BRAF and
KRAS mutations in MSI and MSS stage III colon cancer. J Natl Cancer
Inst 2017;109( 5).
78. Palumbo LT, Sharpe WS, Henry JS. Cancer of the colon and rectum;
analysis of 300 cases. Am J Surg 1965;109:439–44.
79. Sharp GS, Benefiel WW. 5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum. Cancer Chemother Rep
80. Lawrence W Jr, Terz JJ, Horsley JS 3rd, et al. Chemotherapy as an
adjuvant to surgery for colorectal cancer. Ann Surg 1975;181:616–23.
81. Grage TD, et al. Adjuvant chemotherapy with 5-fluorouracil after
surgical resection of colorectal carcinoma (COG protocol 7041). A
preliminary report. Am J Surg 1977;133:59–66.
82. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol
C-01. J Natl Cancer Inst 1988;80: 30–6.
83. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J
84. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary
colon cancer: results from National Surgical Adjuvant Breast and
Bowel Project protocol C-03. J Clin Oncol 1993;11:1879–87.
85. Comparison of fluorouracil with additional levamisole, higher-dose
folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet
86. Chen TC, Hinton DR, Leichman L, et al. Multifocal inflammatory
leukoencephalopathy associated with levamisole and 5-fluorouracil:
case report. Neurosurgery 1994;35:1138-42.
87. Porschen R, Bermann A, Löffler T, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected
stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol
88. Arkenau HT, Bermann A, Rettig K, et al. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage
III colon cancer: long-term follow-up results of the adjCCA-01 trial.
Ann Oncol 2003;14:395–9.
89. Weinerman B, Shah A, Fields A, et al. Systemic infusion versus bolus
chemotherapy with 5-fluorouracil in measurable metastatic colorectal
cancer. Am J Clin Oncol 1992;15:518–23.
90. Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil,
leucovorin, and levamisole versus fluorouracil continuous infusion
and levamisole for adjuvant treatment of stage III and high-risk stage
II colon cancer. J Clin Oncol 2005;23:1819–25.